{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:54:11Z","timestamp":1791518051112,"version":"4.3.4"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T00:00:00Z","timestamp":1668038400000},"content-version":"vor","delay-in-days":892,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1111\/ajt.15913","type":"journal-article","created":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T06:52:53Z","timestamp":1592203973000},"page":"42-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"S4","title":["The role of novel therapeutic approaches for prevention of allosensitization and antibody-mediated rejection"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0456-8635","authenticated-orcid":false,"given":"Stanley C.","family":"Jordan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2121-9397","authenticated-orcid":false,"given":"Noriko","family":"Ammerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jua","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supreet","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiad","family":"Najjar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mieko","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathlyn","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Vo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1111\/ajt.15913_bib1","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/TP.0000000000002462","article-title":"Novel therapeutic approaches to allosensitization and antibody-mediated rejection","volume":"103","author":"Jordan","year":"2019","journal-title":"Transplantation."},{"issue":"12","key":"10.1111\/ajt.15913_bib2","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1056\/NEJMra1802677","article-title":"Antibody-mediated rejection of solid-organ allografts","volume":"379","author":"Loupy","year":"2018","journal-title":"N Engl J Med."},{"issue":"7","key":"10.1111\/ajt.15913_bib3","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1172\/JCI90597","article-title":"Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies","volume":"127","author":"Valenzuela","year":"2017","journal-title":"J Clin Invest."},{"issue":"26","key":"10.1111\/ajt.15913_bib4","first-page":"2600","article-title":"Belatacept and long-term outcomes in kidney transplantation","volume":"374","author":"Vincenti","year":"2016","journal-title":"N Engl J Med."},{"issue":"9","key":"10.1111\/ajt.15913_bib5","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.4049\/jimmunol.1500940","article-title":"Cutting edge: CTLA-4Ig inhibits memory B cell responses and promotes allograft survival in sensitized recipients","volume":"195","author":"Chen","year":"2015","journal-title":"J Immunol."},{"key":"10.1111\/ajt.15913_bib6","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.trim.2016.08.001","article-title":"Immunological characterization of de novo and recall alloantibody suppression by CTLA4Ig in a mouse model of allosensitization","volume":"38","author":"Kim","year":"2016","journal-title":"Transpl Immunol."},{"issue":"12","key":"10.1111\/ajt.15913_bib7","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1681\/ASN.2015070774","article-title":"Anti-CD28 antibody and belatacept exert differential effects on mechanisms of renal allograft rejection","volume":"27","author":"Ville","year":"2016","journal-title":"J Am Soc Nephrol."},{"issue":"3","key":"10.1111\/ajt.15913_bib8","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/ajt.15067","article-title":"Dual targeting: combining costimulation blockade and bortezomib to permit kidney transplantation in sensitized recipients","volume":"19","author":"Burghuber","year":"2019","journal-title":"Am J Transplant."},{"issue":"3","key":"10.1111\/ajt.15913_bib9","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1681\/ASN.2017060679","article-title":"Control of humoral response in renal transplantation by belatacept depends on a direct effect on B cells and impaired T follicular helper-B cell crosstalk","volume":"29","author":"Leibler","year":"2018","journal-title":"J Am Soc Nephrol."},{"issue":"3","key":"10.1111\/ajt.15913_bib10","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/ajt.15229","article-title":"Belatacept in renal transplant recipient with mild immunologic risk factor: a pilot prospective study (BELACOR)","volume":"19","author":"Leibler","year":"2019","journal-title":"Am J Transplant."},{"issue":"3","key":"10.1111\/ajt.15913_bib11","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J Immunol."},{"issue":"3","key":"10.1111\/ajt.15913_bib12","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood."},{"issue":"23","key":"10.1111\/ajt.15913_bib13","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1182\/bloodadvances.2017006866","article-title":"Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma","volume":"1","author":"Casneuf","year":"2017","journal-title":"Blood Adv."},{"key":"10.1111\/ajt.15913_bib14","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.imlet.2018.04.005","article-title":"Immunomodulatory effects of CD38-targeting antibodies","volume":"199","author":"van de Donk","year":"2018","journal-title":"Immunol Lett."},{"issue":"7","key":"10.1111\/ajt.15913_bib15","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1681\/ASN.2018121254","article-title":"Daratumumab in sensitized kidney transplantation: potentials and limitations of experimental and clinical use","volume":"30","author":"Kwun","year":"2019","journal-title":"J Am Soc Nephrol."},{"issue":"15","key":"10.1111\/ajt.15913_bib16","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1158\/1078-0432.CCR-16-3192","article-title":"Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma","volume":"23","author":"Feng","year":"2017","journal-title":"Clin Cancer Res."},{"key":"10.1111\/ajt.15913_bib17","doi-asserted-by":"crossref","unstructured":"Cooper D. Safety and Preliminary Clinical Activity of REGN5458, an Anti-BCMA x Anti-CD3 Bispecific Antibody in Patients with Relapsed\/Refractory Multiple Myeloma, D. Madduri, Editor. 2019, Meeting of American Society of Hematology: Orlando, FL.","DOI":"10.1182\/blood-2019-126818"},{"key":"10.1111\/ajt.15913_bib18","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3389\/fonc.2019.00146","article-title":"Multi targeted CAR-T cell therapies for B-cell malignancies","volume":"9","author":"Shah","year":"2019","journal-title":"Front Oncol."},{"issue":"10206","key":"10.1111\/ajt.15913_bib19","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet."},{"issue":"5","key":"10.1111\/ajt.15913_bib20","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/ni.3153","article-title":"IL-6 as a keystone cytokine in health and disease","volume":"16","author":"Hunter","year":"2015","journal-title":"Nat Immunol."},{"issue":"2","key":"10.1111\/ajt.15913_bib21","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/BOR.0000000000000255","article-title":"The biology behind interleukin-6 targeted interventions","volume":"28","author":"Liu","year":"2016","journal-title":"Curr Opin Rheumatol."},{"issue":"6","key":"10.1111\/ajt.15913_bib22","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.4049\/jimmunol.1401190","article-title":"Cutting edge: circulating plasmablasts induce the differentiation of human T follicular helper cells via IL-6 production","volume":"194","author":"Chavele","year":"2015","journal-title":"J Immunol."},{"issue":"4","key":"10.1111\/ajt.15913_bib23","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/2326-6066.CIR-14-0022","article-title":"The biology and medical implications of interleukin-6","volume":"2","author":"Tanaka","year":"2014","journal-title":"Cancer Immunol Res."},{"issue":"6","key":"10.1111\/ajt.15913_bib24","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nri3227","article-title":"Regulatory immune cells in transplantation","volume":"12","author":"Wood","year":"2012","journal-title":"Nat Rev Immunol."},{"issue":"10","key":"10.1111\/ajt.15913_bib25","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1097\/00007890-199705270-00023","article-title":"Sequential monitoring of urine-soluble interleukin 2 receptor and interleukin 6 predicts acute rejection of human renal allografts before clinical or laboratory signs of renal dysfunction","volume":"63","author":"Casiraghi","year":"1997","journal-title":"Transplantation."},{"issue":"2","key":"10.1111\/ajt.15913_bib26","first-page":"314","article-title":"Interleukin 6 (IL-6) in serum and urine of renal transplant recipients","volume":"71","author":"Van Oers","year":"1988","journal-title":"Clin Exp Immunol."},{"issue":"3","key":"10.1111\/ajt.15913_bib27","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1097\/00007890-199103000-00012","article-title":"Differential in situ expression of cytokines in renal allograft rejection","volume":"51","author":"Vandenbroecke","year":"1991","journal-title":"Transplantation."},{"issue":"9","key":"10.1111\/ajt.15913_bib28","doi-asserted-by":"crossref","first-page":"511","DOI":"10.11622\/smedj.2013174","article-title":"Evaluation of serum interleukin 6 and tumour necrosis factor alpha levels, and their association with various non-immunological parameters in renal transplant recipients","volume":"54","author":"Sonkar","year":"2013","journal-title":"Singapore Med J."},{"issue":"12","key":"10.1111\/ajt.15913_bib29","doi-asserted-by":"crossref","first-page":"e0145258","DOI":"10.1371\/journal.pone.0145258","article-title":"Increase of Th17 cell phenotype in kidney transplant recipients with chronic allograft dysfunction","volume":"10","author":"Chung","year":"2015","journal-title":"PLoS ONE."},{"issue":"Suppl 3","key":"10.1111\/ajt.15913_bib30","article-title":"Differentially expressed IL-6R\u03b1 and GP130 genes in kidney biopsies (Bxs) suggests different roles of IL-6 signaling in antibody (ABMR)- and cell (CMR)-mediated rejection [abstract]","volume":"15","author":"Zhang","year":"2015","journal-title":"Am J Transplant."},{"issue":"9","key":"10.1111\/ajt.15913_bib31","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1111\/ajt.14228","article-title":"Assessment of tocilizumab (anti-interleukin-6 receptor monoclonal) as a potential treatment for chronic antibody-mediated rejection and transplant glomerulopathy in HLA-sensitized renal allograft recipients","volume":"17","author":"Choi","year":"2017","journal-title":"Am J Transplant."},{"issue":"5","key":"10.1111\/ajt.15913_bib32","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1111\/ajt.13644","article-title":"HLA class II antibody activation of endothelial cells promotes Th17 and disrupts regulatory T lymphocyte expansion","volume":"16","author":"Lion","year":"2016","journal-title":"Am J Transplant."},{"issue":"Suppl 3","key":"10.1111\/ajt.15913_bib33","article-title":"Clazakizumab acts on endothelial cells to limit antibody mediated damage [abstract]","volume":"19","author":"Lion","year":"2019","journal-title":"Am J Transplant."},{"issue":"33","key":"10.1111\/ajt.15913_bib34","doi-asserted-by":"crossref","first-page":"55230","DOI":"10.18632\/oncotarget.19420","article-title":"Overriding TKI resistance of renal cell carcinoma by combination therapy with IL-6 receptor blockade","volume":"8","author":"Ishibashi","year":"2017","journal-title":"Oncotarget."},{"issue":"Suppl 3","key":"10.1111\/ajt.15913_bib35","article-title":"Non-human primate lung allograft survival is prolonged by il-6 inhibition and ATG treatment possibly through expansion of peripheral regulatory Tcells. [abstract]. American Transplant Congress","volume":"16","author":"Aoyama","year":"2016","journal-title":"Am J Transplant."},{"issue":"Suppl 4","key":"10.1111\/ajt.15913_bib36","first-page":"424","article-title":"IL-6 inhibition with tocilizumab to promote tregs and control renal graft inflammation: a prospective randomized controlled trial [abstract]","volume":"18","author":"Chandran","year":"2018","journal-title":"Am J Transplant."},{"issue":"Suppl 4","key":"10.1111\/ajt.15913_bib37","first-page":"521","article-title":"Immunologic Impact of tocilizumab treatment in kidney transplant recipients with allograft inflammation [abstract]","volume":"18","author":"Leung","year":"2018","journal-title":"Am J Transplant."},{"key":"10.1111\/ajt.15913_bib38","doi-asserted-by":"crossref","first-page":"e543","DOI":"10.1097\/TXD.0000000000000988","article-title":"Efficacy and safety of tocilizumab in the treatment of acute active antibody-mediated rejection in kidney transplant recipients","volume":"6","author":"Pottebaum","year":"2020","journal-title":"Transplant Direct"},{"key":"10.1111\/ajt.15913_bib39","doi-asserted-by":"crossref","unstructured":"Jordan SC, Ammerman N, Choi J, et al. Interleukin 6: pathogenic potential and therapeutic approaches in autoimmunity and transplant rejection. 2018;1-12.","DOI":"10.1002\/9780470015902.a0028204"},{"issue":"10","key":"10.1111\/ajt.15913_bib40","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1002\/art.39249","volume":"67","author":"Weinblatt","year":"2015","journal-title":"Arthritis Rheumatol."},{"issue":"suppl 3","key":"10.1111\/ajt.15913_bib41","first-page":"452","article-title":"Clazakizumab as an agent to reduce donor specific HLA antibodies and improve outcomes in patients with chronic & active antibody-mediated rejection post-kidney transplantation","volume":"19","author":"Jordan","year":"2019","journal-title":"Am J Transplant."},{"key":"10.1111\/ajt.15913_bib42","unstructured":"Clazakizumab for chronic and active antibody mediated rejection post-kidney transplant. https:\/\/ClinicalTrials.gov\/show\/NCT03380377."},{"key":"10.1111\/ajt.15913_bib43","unstructured":"A pilot trial of clazakizumab in late ABMR. https:\/\/ClinicalTrials.gov\/show\/NCT03444103."},{"key":"10.1111\/ajt.15913_bib44","unstructured":"Interleukin 6 blockade modifying antibody-mediated graft injury and estimated glomerular filtration rate (eGFR) decline (IMAGINE). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03744910."},{"issue":"1","key":"10.1111\/ajt.15913_bib45","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/s41467-019-09092-2","article-title":"A late B lymphocyte action in dysfunctional tissue repair following kidney injury and transplantation","volume":"10","author":"Cipp\u00e0","year":"2019","journal-title":"Nat Commun."},{"issue":"11","key":"10.1111\/ajt.15913_bib46","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1111\/ajt.14328","article-title":"Complement dependence of murine costimulatory blockade-resistant cellular cardiac allograft rejection","volume":"17","author":"Chun","year":"2017","journal-title":"Am J Transplant."},{"issue":"1","key":"10.1111\/ajt.15913_bib47","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cll.2018.10.004","article-title":"Complement and transplantation: from new mechanisms to potential biomarkers and novel treatment strategies","volume":"39","author":"Horwitz","year":"2019","journal-title":"Clin Lab Med."},{"issue":"6","key":"10.1111\/ajt.15913_bib48","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/MOT.0000000000000708","article-title":"Linking innate immunity and chronic antibody-mediated allograft rejection","volume":"24","author":"Gill","year":"2019","journal-title":"Curr Opin Organ Transplant."},{"issue":"12","key":"10.1111\/ajt.15913_bib49","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1111\/ajt.14767","article-title":"A phase I\/II, double-blind, placebo-controlled study assessing safety and efficacy of C1 esterase inhibitor for prevention of delayed graft function in deceased donor kidney transplant recipients","volume":"18","author":"Jordan","year":"2018","journal-title":"Am J Transplant."},{"issue":"1","key":"10.1111\/ajt.15913_bib50","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2215\/CJN.04840419","article-title":"Three-year outcomes of a randomized, double-blind, placebo-controlled study assessing safety and efficacy of C1 esterase inhibitor for prevention of delayed graft function in deceased donor kidney transplant recipients","volume":"15","author":"Huang","year":"2020","journal-title":"Clin J Am Soc Nephrol."},{"issue":"2","key":"10.1111\/ajt.15913_bib51","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/TP.0000000000000592","article-title":"A phase I\/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients","volume":"99","author":"Vo","year":"2015","journal-title":"Transplantation."},{"issue":"5","key":"10.1111\/ajt.15913_bib52","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1111\/ajt.13663","article-title":"C1 inhibitor in acute antibody-mediated rejection nonresponsive to conventional therapy in kidney transplant recipients: a pilot study","volume":"16","author":"Viglietti","year":"2016","journal-title":"Am J Transplant."},{"issue":"9","key":"10.1111\/ajt.15913_bib53","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1097\/TP.0000000000002717","article-title":"Update on C1 esterase inhibitor in human solid organ transplantation","volume":"103","author":"Berger","year":"2019","journal-title":"Transplantation."},{"issue":"12","key":"10.1111\/ajt.15913_bib54","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1111\/ajt.13871","article-title":"Plasma-derived C1 esterase inhibitor for acute antibody-mediated rejection following kidney transplantation: results of a randomized double-blind placebo-controlled pilot study","volume":"16","author":"Montgomery","year":"2016","journal-title":"Am J Transplant."},{"key":"10.1111\/ajt.15913_bib55","unstructured":"Efficacy and safety of human plasma-derived C1-esterase inhibitor as add-on to standard of care for the treatment of refractory antibody mediated rejection (AMR) in adult renal transplant recipients. https:\/\/ClinicalTrials.gov\/show\/NCT03221842."},{"key":"10.1111\/ajt.15913_bib56","unstructured":"A multicenter study to evaluate the efficacy and safety of Cinryze\u00ae for the treatment of acute antibody-mediated rejection in patients with kidney transplant. https:\/\/ClinicalTrials.gov\/show\/NCT02547220."},{"key":"10.1111\/ajt.15913_bib57","first-page":"3197042","article-title":"Eculizumab for thrombotic microangiopathy associated with antibody-mediated rejection after ABO-incompatible kidney transplantation","volume":"2017","author":"Lanfranco","year":"2017","journal-title":"Case Rep Transplant."},{"issue":"1","key":"10.1111\/ajt.15913_bib58","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1600-6143.2008.02451.x","article-title":"The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection","volume":"9","author":"Locke","year":"2009","journal-title":"Am J Transplant."},{"issue":"3","key":"10.1111\/ajt.15913_bib59","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.transproceed.2013.02.062","article-title":"Eculizumab for salvage treatment of refractory antibody-mediated rejection in kidney transplant patients: case reports","volume":"45","author":"Kocak","year":"2013","journal-title":"Transplant Proc."},{"issue":"1","key":"10.1111\/ajt.15913_bib60","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1111\/petr.12187","article-title":"Plasmapheresis-resistant acute humoral rejection successfully treated with anti-C5 antibody","volume":"18","author":"Ghirardo","year":"2014","journal-title":"Pediatr Transplant."},{"issue":"2","key":"10.1111\/ajt.15913_bib61","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1681\/ASN.2017050589","article-title":"Complement-activating anti-HLA antibodies in kidney transplantation: allograft gene expression profiling and response to treatment","volume":"29","author":"Lefaucheur","year":"2018","journal-title":"J Am Soc Nephrol."},{"issue":"11","key":"10.1111\/ajt.15913_bib62","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1097\/TP.0000000000002267","article-title":"Novel approaches to block complement","volume":"102","author":"B\u00f6hmig","year":"2018","journal-title":"Transplantation."},{"issue":"4","key":"10.1111\/ajt.15913_bib63","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.kint.2018.03.015","article-title":"Complement-binding anti-HLA antibodies are independent predictors of response to treatment in kidney recipients with antibody-mediated rejection","volume":"94","author":"Viglietti","year":"2018","journal-title":"Kidney Int."},{"issue":"11","key":"10.1111\/ajt.15913_bib64","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1097\/TP.0000000000002639","article-title":"Use of eculizumab for active antibody-mediated rejection that occurs early post-kidney transplantation: a consecutive series of 15 cases","volume":"103","author":"Tan","year":"2019","journal-title":"Transplantation."},{"issue":"10","key":"10.1111\/ajt.15913_bib65","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1111\/ajt.15397","article-title":"Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies","volume":"19","author":"Glotz","year":"2019","journal-title":"Am J Transplant."},{"issue":"4","key":"10.1111\/ajt.15913_bib66","doi-asserted-by":"crossref","first-page":"e0195909","DOI":"10.1371\/journal.pone.0195909","article-title":"Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action","volume":"13","author":"Sheridan","year":"2018","journal-title":"PLoS ONE."},{"issue":"17","key":"10.1111\/ajt.15913_bib67","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/bloodadvances.2018020644","article-title":"Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b\/2 studies","volume":"2","author":"R\u00f6th","year":"2018","journal-title":"Blood Adv."},{"issue":"1","key":"10.1111\/ajt.15913_bib68","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/TP.0000000000002912","article-title":"Implications of Fc neonatal receptor (FcRn) manipulations for transplant immunotherapeutics","volume":"104","author":"Jordan","year":"2020","journal-title":"Transplantation."},{"issue":"4","key":"10.1111\/ajt.15913_bib69","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/ajt.14528","article-title":"Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejection-results from a first-in-patient phase 1 trial","volume":"18","author":"Eskandary","year":"2018","journal-title":"Am J Transplant."},{"key":"10.1111\/ajt.15913_bib70","unstructured":"Safety tolerability and activity of TNT009 in healthy volunteers and patients with complement mediated disorders. https:\/\/ClinicalTrials.gov\/show\/NCT02502903."},{"issue":"5","key":"10.1111\/ajt.15913_bib71","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1056\/NEJMoa1612567","article-title":"IgG endopeptidase in highly sensitized patients undergoing transplantation","volume":"377","author":"Jordan","year":"2017","journal-title":"N Engl J Med."},{"issue":"7","key":"10.1111\/ajt.15913_bib72","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1093\/emboj\/21.7.1607","article-title":"IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G","volume":"21","author":"von Pawel-Rammingen","year":"2002","journal-title":"EMBO J."},{"issue":"6","key":"10.1111\/ajt.15913_bib73","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1124\/mol.113.086470","article-title":"Therapeutic cleavage of anti-aquaporin-4 autoantibody in neuromyelitis optica by an IgG-selective proteinase","volume":"83","author":"Tradtrantip","year":"2013","journal-title":"Mol Pharmacol."},{"key":"10.1111\/ajt.15913_bib74","unstructured":"Phase II study, evaluation of safety and efficacy of ides in chronic kidney disease. https:\/\/ClinicalTrials.gov\/show\/NCT02224820."},{"key":"10.1111\/ajt.15913_bib75","doi-asserted-by":"crossref","first-page":"5672523","DOI":"10.1155\/2017\/5672523","article-title":"Impact of desensitization on antiviral immunity in hla-sensitized kidney transplant recipients","volume":"2017","author":"Toyoda","year":"2017","journal-title":"J Immunol Res."},{"key":"10.1111\/ajt.15913_bib76","doi-asserted-by":"crossref","unstructured":"Ge S, Chu M, Choi J, et al. Imlifidase inhibits HLA antibody-mediated NK cell activation and antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro. Transplantation. 2019. https:\/\/doi.org\/10.1097\/TP.0000000000003023","DOI":"10.1097\/TP.0000000000003023"},{"key":"10.1111\/ajt.15913_bib77","unstructured":"An efficacy and safety study of imlifidase in treatment of antibody-mediated rejection in kidney transplant patients. NCT03897205."},{"issue":"7","key":"10.1111\/ajt.15913_bib78","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1111\/ajt.15366","article-title":"The neonatal Fc receptor: Key to homeostasic control of IgG and IgG-related biopharmaceuticals","volume":"19","author":"Baldwin","year":"2019","journal-title":"Am J Transplant."},{"issue":"2","key":"10.1111\/ajt.15913_bib79","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1600-6143.2010.03400.x","article-title":"Clinical aspects of intravenous immunoglobulin use in solid organ transplant recipients","volume":"11","author":"Jordan","year":"2011","journal-title":"Am J Transplant."},{"issue":"21","key":"10.1111\/ajt.15913_bib80","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1056\/NEJMra1009433","article-title":"Intravenous immune globulin in autoimmune and inflammatory diseases","volume":"367","author":"Gelfand","year":"2012","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1111\/ajt.15913_bib81","doi-asserted-by":"crossref","first-page":"5141","DOI":"10.1038\/s41598-018-23481-5","article-title":"In vivo depletion of serum IgG by an affibody molecule binding the neonatal Fc receptor","volume":"8","author":"Seijsing","year":"2018","journal-title":"Sci Rep."},{"issue":"414","key":"10.1111\/ajt.15913_bib82","doi-asserted-by":"crossref","first-page":"eaan1208","DOI":"10.1126\/scitranslmed.aan1208","article-title":"The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: a randomized phase 1 study","volume":"9","author":"Kiessling","year":"2017","journal-title":"Sci Transl Med."},{"issue":"10","key":"10.1111\/ajt.15913_bib83","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1182\/blood.V98.10.3136","article-title":"Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect","volume":"98","author":"Bleeker","year":"2001","journal-title":"Blood."},{"issue":"12","key":"10.1111\/ajt.15913_bib84","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1172\/JCI24394","article-title":"Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases","volume":"115","author":"Li","year":"2005","journal-title":"J Clin Invest."},{"issue":"6","key":"10.1111\/ajt.15913_bib85","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1055\/s-0037-1613331","article-title":"Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor","volume":"88","author":"Hansen","year":"2002","journal-title":"Thromb Haemost."},{"issue":"4","key":"10.1111\/ajt.15913_bib86","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/ajt.14520","article-title":"Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: a multicenter, prospective, randomized, double-blind clinical trial","volume":"18","author":"Moreso","year":"2018","journal-title":"Am J Transplant."},{"issue":"3","key":"10.1111\/ajt.15913_bib87","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1600-6143.2009.03005.x","article-title":"A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study)","volume":"10","author":"Vincenti","year":"2010","journal-title":"Am J Transplant."},{"issue":"3","key":"10.1111\/ajt.15913_bib88","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1600-6143.2010.03016.x","article-title":"A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study)","volume":"10","author":"Durrbach","year":"2010","journal-title":"Am J Transplant."}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajt.15913","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajt.15913","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajt.15913","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522225969?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522225969?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajt.15913","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:29:26Z","timestamp":1761629366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613522225969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":88,"alternative-id":["S1600613522225969"],"URL":"https:\/\/doi.org\/10.1111\/ajt.15913","relation":{},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of novel therapeutic approaches for prevention of allosensitization and antibody-mediated rejection","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/ajt.15913","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}